Thrita

Published by: Kowsar

Analysis of the Potential Associations of Two Common Polymorphisms in the ABCC1 Three Prime Untranslated Region With Breast Cancer Susceptibility

Zahra Salehi 1 , Arshad Hosseini 1 , * , Mohammad Najafi 2 , Hussain Ahmad 3 and Mohammad Reza Fayazi 4
Authors Information
1 Department of Medical Biotechnology, School of Allied Medicine, Iran University of Medical Sciences, Tehran, IR Iran
2 Department of Biochemistry, School of Medicine, Iran University of Medical Sciences, Tehran, IR Iran
3 Department of Medical Biotechnology, School of Advanced Technologies in Medicine, International Campus, Tehran University of Medical Sciences, Tehran, IR Iran
4 Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, IR Iran
Article information
  • Thrita: June 01, 2016, 5 (2); e35121
  • Published Online: May 17, 2016
  • Article Type: Brief Report
  • Received: November 29, 2015
  • Revised: December 20, 2015
  • Accepted: January 11, 2016
  • DOI: 10.5812/thritaj.35121

To Cite: Salehi Z, Hosseini A, Najafi M, Ahmad H, Fayazi M R. et al. Analysis of the Potential Associations of Two Common Polymorphisms in the ABCC1 Three Prime Untranslated Region With Breast Cancer Susceptibility, Thrita. 2016 ;5(2):e35121. doi: 10.5812/thritaj.35121.

Abstract
Copyright © 2016, Thrita. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
Footnote
References
  • 1. Florea AM, Büsselberg D. Breast cancer and possible mechanisms of therapy resistance. J Local Global Health Sci. 2013; 2: 1-12
  • 2. Giordano SH, Buzdar AU, Smith TL, Kau SW, Yang Y, Hortobagyi GN. Is breast cancer survival improving? Cancer. 2004; 100(1): 44-52[DOI][PubMed]
  • 3. Valero V, Holmes FA, Walters RS, Theriault RL, Esparza L, Fraschini G, et al. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol. 1995; 13(12): 2886-94[PubMed]
  • 4. Wu CP, Calcagno AM, Ambudkar SV. Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies. Curr Mol Pharmacol. 2008; 1(2): 93-105[PubMed]
  • 5. Pogribny IP, Filkowski JN, Tryndyak VP, Golubov A, Shpyleva SI, Kovalchuk O. Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin. Int J Cancer. 2010; 127(8): 1785-94[DOI][PubMed]
  • 6. Munoz M, Henderson M, Haber M, Norris M. Role of the MRP1/ABCC1 multidrug transporter protein in cancer. IUBMB Life. 2007; 59(12): 752-7[DOI][PubMed]
  • 7. Wang Z, Li Y, Ahmad A, Azmi AS, Kong D, Banerjee S, et al. Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistance. Drug Resist Updat. 2010; 13(4-5): 109-18[DOI][PubMed]
  • 8. Cole SP. Targeting multidrug resistance protein 1 (MRP1, ABCC1): past, present, and future. Annu Rev Pharmacol Toxicol. 2014; 54: 95-117[DOI][PubMed]
  • 9. Gradhand U, Kim RB. Pharmacogenomics of MRP transporters (ABCC1-5) and BCRP (ABCG2). Drug Metab Rev. 2008; 40(2): 317-54[DOI][PubMed]
  • 10. Cho S, Lu M, He X, Ee PL, Bhat U, Schneider E, et al. Notch1 regulates the expression of the multidrug resistance gene ABCC1/MRP1 in cultured cancer cells. Proc Natl Acad Sci U S A. 2011; 108(51): 20778-83[DOI][PubMed]
  • 11. Pan YZ, Zhou A, Hu Z, Yu AM. Small nucleolar RNA-derived microRNA hsa-miR-1291 modulates cellular drug disposition through direct targeting of ABC transporter ABCC1. Drug Metab Dispos. 2013; 41(10): 1744-51[DOI][PubMed]
  • 12. Yin J, Zhang J. Multidrug resistance-associated protein 1 (MRP1/ABCC1) polymorphism: from discovery to clinical application. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2011; 36(10): 927-38[DOI][PubMed]
  • 13. Pan YZ, Yu A. A novel small nucleolar RNA-derived microRNA-1291 targets multidrug resistance-associated protein 1 (MRP1/ABCC1). FASEB J. 2011; 25: 1015
  • 14. Ma J, Wang T, Guo R, Yang X, Yin J, Yu J, et al. Involvement of miR-133a and miR-326 in ADM resistance of HepG2 through modulating expression of ABCC1. J Drug Target. 2015; 23(6): 519-24[DOI][PubMed]
  • 15. Monzo M, Navarro A, Ferrer G, Artells R. Pharmacogenomics: a tool for improving cancer chemotherapy. Clin Transl Oncol. 2008; 10(10): 628-37[PubMed]
  • 16. Kim S, Misra A. SNP genotyping: technologies and biomedical applications. Annu Rev Biomed Eng. 2007; 9: 289-320[DOI][PubMed]
  • 17. Marsh S, Paul J, King CR, Gifford G, McLeod HL, Brown R. Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. J Clin Oncol. 2007; 25(29): 4528-35[DOI][PubMed]
  • 18. Vulsteke C, Lambrechts D, Dieudonne A, Hatse S, Brouwers B, van Brussel T, et al. Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC). Ann Oncol. 2013; 24(6): 1513-25[DOI][PubMed]
  • 19. Zhao J, Yu BY, Wang DY, Yang JE. Promoter polymorphism of MRP1 associated with reduced survival in hepatocellular carcinoma. World J Gastroenterol. 2010; 16(48): 6104-10[PubMed]
  • 20. Multidrug Resistance-Associated Protein-1 (MRP1) Genetic Variants and Severity of Chronic Obstructive Pulmonary Disease (COPD). American Journal of Respiratory And Critical Care Medicine.
  • 21. Wang H, Jin G, Wang H, Liu G, Qian J, Jin L, et al. Genetic susceptibility of lung cancer associated with common variants in the 3' untranslated regions of the adenosine triphosphate-binding cassette B1 (ABCB1) and ABCC1 candidate transporter genes for carcinogen export. Cancer. 2009; 115(3): 595-607[DOI][PubMed]
  • 22. Steeghs N, Gelderblom H, Wessels J, Eskens FA, de Bont N, Nortier JW, et al. Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors. Invest New Drugs. 2011; 29(1): 137-43[DOI][PubMed]
  • 23. Coelho AV, Silva SP, de Alencar LC, Stocco G, Crovella S, Brandao LA, et al. ABCB1 and ABCC1 variants associated with virological failure of first-line protease inhibitors antiretroviral regimens in Northeast Brazil patients. J Clin Pharmacol. 2013; 53(12): 1286-93[DOI][PubMed]
  • 24. Abaan OD, Mutlu PK, Baran Y, Atalay C, Gunduz U. Multidrug resistance mediated by MRP1 gene overexpression in breast cancer patients. Cancer Invest. 2009; 27(2): 201-5[DOI][PubMed]
  • 25. Filipits M, Malayeri R, Suchomel RW, Pohl G, Stranzl T, Dekan G, et al. Expression of the multidrug resistance protein (MRP1) in breast cancer. Anticancer Res. 1999; 19(6B): 5043-9[PubMed]
  • 26. Atalay C, Deliloglu Gurhan I, Irkkan C, Gunduz U. Multidrug resistance in locally advanced breast cancer. Tumour Biol. 2006; 27(6): 309-18[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments